4/6
07:04 am
bcrx
BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer [Yahoo! Finance]
Medium
Report
BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer [Yahoo! Finance]
4/6
07:00 am
bcrx
BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer
Medium
Report
BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer
4/5
03:33 pm
bcrx
How The BioCryst Pharmaceuticals (BCRX) Narrative Is Shifting With Astria Deal And FY26 Targets [Yahoo! Finance]
Medium
Report
How The BioCryst Pharmaceuticals (BCRX) Narrative Is Shifting With Astria Deal And FY26 Targets [Yahoo! Finance]
4/3
07:00 am
bcrx
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/19
01:28 pm
bcrx
BioCryst Pharmaceuticals, Inc. (BCRX) A Good Stock To Buy Now? [Yahoo! Finance]
Low
Report
BioCryst Pharmaceuticals, Inc. (BCRX) A Good Stock To Buy Now? [Yahoo! Finance]
3/17
11:03 am
bcrx
BioCryst: The Buyout Rumor Is Noise, The Franchise Is Real [Seeking Alpha]
Low
Report
BioCryst: The Buyout Rumor Is Noise, The Franchise Is Real [Seeking Alpha]
3/17
12:55 am
bcrx
BioCryst (BCRX) Soars 13% on Acquisition Buzz [Yahoo! Finance]
Low
Report
BioCryst (BCRX) Soars 13% on Acquisition Buzz [Yahoo! Finance]
3/10
08:10 am
bcrx
BioCryst Pharma (BCRX) Subject to Prise Target Raise by Wedbush [Yahoo! Finance]
Low
Report
BioCryst Pharma (BCRX) Subject to Prise Target Raise by Wedbush [Yahoo! Finance]
3/6
06:09 am
bcrx
BioCryst Pharmaceuticals (BCRX) was upgraded by
Weiss Ratings from "sell (d-)" to "hold (c)".
Low
Report
BioCryst Pharmaceuticals (BCRX) was upgraded by
Weiss Ratings from "sell (d-)" to "hold (c)".
3/4
07:25 am
bcrx
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
3/4
07:00 am
bcrx
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/2
04:43 am
bcrx
A Look At BioCryst Pharmaceuticals (BCRX) Valuation As Net Income Turns Positive And Astria Deal Expands HAE Portfolio [Yahoo! Finance]
Low
Report
A Look At BioCryst Pharmaceuticals (BCRX) Valuation As Net Income Turns Positive And Astria Deal Expands HAE Portfolio [Yahoo! Finance]
3/1
07:02 pm
bcrx
BioCryst's First Profitable Year Recasts Hereditary Angioedema Growth Story [Yahoo! Finance]
Low
Report
BioCryst's First Profitable Year Recasts Hereditary Angioedema Growth Story [Yahoo! Finance]
2/28
07:38 am
bcrx
BioCryst (BCRX) Soars 10.8% on Swing to Profits [Yahoo! Finance]
Low
Report
BioCryst (BCRX) Soars 10.8% on Swing to Profits [Yahoo! Finance]
2/27
12:00 am
bcrx
Where is BioCryst Pharmaceuticals (BCRX) Headed According to the Street? [Yahoo! Finance]
High
Report
Where is BioCryst Pharmaceuticals (BCRX) Headed According to the Street? [Yahoo! Finance]
2/26
04:42 pm
bcrx
BioCryst Pharmaceuticals Inc (BCRX) Q4 2025 Earnings Call Highlights: Record Profitability and ... [Yahoo! Finance]
High
Report
BioCryst Pharmaceuticals Inc (BCRX) Q4 2025 Earnings Call Highlights: Record Profitability and ... [Yahoo! Finance]
2/26
07:32 am
bcrx
BioCryst Reports Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
BioCryst Reports Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]
2/26
07:00 am
bcrx
BioCryst Reports Full Year 2025 Financial Results and Provides Business Update
Low
Report
BioCryst Reports Full Year 2025 Financial Results and Provides Business Update
2/25
01:39 pm
bcrx
Are BioCryst Pharmaceuticals (BCRX) Shares Offering Value After Recent Price Rebound [Yahoo! Finance]
Low
Report
Are BioCryst Pharmaceuticals (BCRX) Shares Offering Value After Recent Price Rebound [Yahoo! Finance]
2/18
08:43 am
bcrx
BioCryst Pharmaceuticals (NASDAQ:BCRX) is now covered by analysts at Evercore Inc. They set an "outperform" rating and a $17.00 price target on the stock.
Medium
Report
BioCryst Pharmaceuticals (NASDAQ:BCRX) is now covered by analysts at Evercore Inc. They set an "outperform" rating and a $17.00 price target on the stock.
2/17
07:00 am
bcrx
BioCryst to Present at Upcoming Investor Conference
Low
Report
BioCryst to Present at Upcoming Investor Conference
2/11
07:00 am
bcrx
BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting
Medium
Report
BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting
2/7
01:03 am
bcrx
Jim Cramer on BioCryst Pharmaceuticals: “Just Stay Away From That” [Yahoo! Finance]
Low
Report
Jim Cramer on BioCryst Pharmaceuticals: “Just Stay Away From That” [Yahoo! Finance]
2/5
07:01 am
bcrx
BioCryst to Report Fourth Quarter 2025 Financial Results on February 26
Medium
Report
BioCryst to Report Fourth Quarter 2025 Financial Results on February 26
2/5
07:00 am
bcrx
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)